The Real Message Behind Commercial mRNA Products eBook
Read the article:
Learning to Think at Lightspeed
Read the eBook:
Pharmaceutical Technology’s The Real Message Behind Commercial mRNA Products eBook
Learning to Think at Lightspeed
By Chris Spivey
Publication
Article
Pharmaceutical TechnologyThe Real Message Behind Commercial mRNA Products, April 2023 eBook
Volume 2023 eBook
Issue 3
Pages: 6–11
Actions combatting the next pandemic must be diverse, reliable, and sustainable.
mylisa - Stock.adobe.com
World leaders have set ambitious goals to respond more swiftly to the next pandemic, including the United States’ goal to design, test, and review a new vaccine just 100 days after a pandemic declaration and to produce enough vaccines for the US and the world in 130 and 200 days. Past preparedness efforts have focused on innovation and reliability—culminating in the novel mRNA vaccines. Today, it’s important to consider diverse responses—and how the industry can make investments sustainable and “ready” for when an emergency happens.
Read this article in Pharmaceutical Technology’s The Real Message Behind Commercial mRNA Products eBook
About the author
Chris Spivey is editorial director of Pharmaceutical Technology.
Article details
Pharmaceutical Technology
eBook: The Real Message Behind Commercial mRNA Products
April 2023
Pages: 6–11
Citation
When referring to this article, please cite it as Spivey, C. Learning to Think at Lightspeed. Pharmaceutical Technology's The Real Message Behind Commercial mRNA Products eBook (April 2023).
Articles in this issue
Stability in mRNA-LNP Formulations
Nucleic Acid-based Therapeutics Are Stepping into the Spotlight
Learning to Think at Lightspeed
Managing mRNA Instability
The Role of Separation Techniques in the Analysis of mRNA Therapeutic Drug Substances and Drug Products
The Marriage of RNA and Mass Spectrometry
Delivering on the Potential of mRNA Therapeutics
The COVID-19 Pandemic and Its Positive Impact on RNA Drug Development
Recent Videos
Related Content
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024Podcast
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024Podcast
In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
